Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. Background: With >5 yrs of clinical experience with SOR, a well-defined efficacy and safety profile has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results